Literature DB >> 12753311

Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.

Rachel A Burdick1, Jennifer L Bragg-Gresham, John D Woods, Sara A Hedderwick, Kiyoshi Kurokawa, Christian Combe, Akira Saito, John LaBrecque, Friedrich K Port, Eric W Young.   

Abstract

BACKGROUND: Hepatitis B (HBV) historically has been a public health issue within hemodialysis units. This study estimates HBV prevalence and seroconversion rates across seven countries and investigates associations with facility level practice patterns.
METHODS: The study sample was from the Dialysis Outcomes and Practice Patterns Study (DOPPS), a cross-sectional, prospective, observational study of adult hemodialysis patients randomly selected from 308 dialysis facilities in France, Germany, Italy, Spain, the United Kingdom, Japan, and the United States. Logistic regression was used to model the odds ratio (OR) of HBV prevalence, and Cox regression was used to model time from entry into the study to HBV seroconversion.
RESULTS: In this sample, mean HBV facility prevalence was 3.0% with a median of 1.9%. The percentage of facilities with an HBV prevalence 0% to 5% was 78.5%. Adjusted HBV prevalence was higher in France, Germany, and Italy and lower in Japan and the United Kingdom. The majority of facilities (78.1%) had a seroconversion rate of 0 conversions per 100 patient-years. Presence of a protocol for HBV-infected patients was significantly associated with HBV seroconversion in the separate practice pattern model [risk ratio (RR) = 0.52, P = 0.03] and in the combined practice pattern model (RR = 0.44, P = 0.01).
CONCLUSION: There are differences in HBV prevalence and rate of seroconversion both at the country and the hemodialysis facility level. Presence of a protocol for HBV-infected patients was strongly and significantly associated with decreased risk for seroconversion. The observed variation suggests opportunities for improved HBV outcomes with further definition of optimal practice patterns at the facility level.

Entities:  

Mesh:

Year:  2003        PMID: 12753311     DOI: 10.1046/j.1523-1755.2003.00017.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

1.  Meta-analysis: the impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease.

Authors:  Fabrizio Fabrizi; Vivek Dixit; Paul Martin; Michel Jadoul; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2011-12-06       Impact factor: 3.199

Review 2.  Immune response to hepatitis B vaccine among patients on hemodialysis.

Authors:  Gasim I Gasim; Abdelhaleem Bella; Ishag Adam
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Antiviral treatment for chronic hepatitis B in renal transplant patients.

Authors:  Ezequiel Ridruejo
Journal:  World J Hepatol       Date:  2015-02-27

Review 4.  Chronic viral hepatitis in kidney transplantation.

Authors:  Janna Huskey; Alexander C Wiseman
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

Review 5.  Characteristics of the clinical practice patterns of hemodialysis in Japan in consideration of DOPPS and the NKF/DOQI guidelines.

Authors:  Satoru Kuriyama
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

6.  Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients.

Authors:  Alba Vilajeliu; Víctor-Guillermo Sequera; Alberto L García-Basteiro; Elisa Sicuri; Marta Aldea; César Velasco; José M Bayas
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

Review 7.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

8.  A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients.

Authors:  E Elhanan; M Boaz; I Schwartz; D Schwartz; G Chernin; H Soetendorp; A Gal Oz; A Agbaria; T Weinstein
Journal:  Clin Exp Nephrol       Date:  2017-04-29       Impact factor: 2.801

9.  Blood-borne viral infections in pediatric hemodialysis.

Authors:  Shina Menon; Raj Munshi
Journal:  Pediatr Nephrol       Date:  2018-07-21       Impact factor: 3.714

Review 10.  Current hepatitis B virus infection situation in Indonesia and its genetic diversity.

Authors:  Maria Inge Lusida; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.